Saturday, 20 October 2018
Lex Eggermont- outlook for Stage 3 Melanoma
Again- tumorload below 0.1 equals no tumour load in the sentinel node in Stage 3A- check out the Rotterdam criteria
Reported in detail at ASCO this year
when we look at OS data from adjuvant treatment, this is a combined result from the adjuvant treatment plus any following therapy
and there is no gain possible- so missed adjuvant, you cannot recover in the metastatic session
There will be an update on the PD1 adjuvant OS by Georgina Long on Monday morning
OS curves from adjuvant Melanoma between targeted therapy and immune therapy appear to cross at about 2 years
'The end of Interferon (in the rich world) but then- he DOES find a use for his Interferon....but please *just* for the ulcerated primaries due to different disease biology
Check out Danielle Verver's publications- there are alternatives to identify the prognosis than CLND
IO combinations: Nivo with Ipi low/ T-Vec
Fake News and Pseudoscience are dangerous for patients. So very pleased and incredibly proud to see Gilly's session covered on the ...
Why treating early stage patients? Early stage patients have all the favourable disease outcomes that we know from Stage 4 cancer immu...
Also this year- updates from ESMO! The program is available online here
Rotterdam criteria Again- tumorload below 0.1 equals no tumour load in the sentinel node in Stage 3A- check out the Rotterdam criteria ...